Literature DB >> 12466481

Studies on the different conditions for rabies virus neutralization by monoclonal antibodies #1-46-12 and #7-1-9.

Takashi Irie1, Akihiko Kawai1.   

Abstract

Virus-neutralizing activity of two monoclonal antibodies (mAbs), #7-1-9 and #1-46-12, against rabies virus glycoprotein (G) was compared. Although these mAbs affected the virion's ability to bind to host cells similarly, a big difference was found in the titres of virus neutralization (1:7132 and 1:32 for mAbs #1-46-12 and #7-1-9, respectively, at a concentration of 10 micro g protein/ml). Although no big difference in virion-binding affinity between the two mAbs was found, the number of antibodies required for virus neutralization was very low, </=20 molecules for mAb #1-46-12 and >/=250 molecules for mAb #7-1-9. In the latter case, the mAbs cover a major part of the virion surface and cause steric hindrance of viral receptor-binding activity. The infectivity of an epitope-preserved escape mutant virus (R-61) was not affected by the binding of high numbers of mAb #1-46-12 to the virion, which implies that mAb binding does not mask the receptor-binding site of the viral spikes. Based on these results, it is hypothesized that mAb #1-46-12 affected virus infectivity by a mechanism different from covering the virion spikes. Possible virus-neutralizing mechanisms by low numbers of mAb #1-46-12 in comparison to that of mAb #7-1-9 are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466481     DOI: 10.1099/0022-1317-83-12-3045

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Sindbis virus conformational changes induced by a neutralizing anti-E1 monoclonal antibody.

Authors:  Raquel Hernandez; Angel Paredes; Dennis T Brown
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

2.  Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus.

Authors:  Chen Li; Feng Zhang; Hong Lin; Zhong-can Wang; Xin-jian Liu; Zhen-qing Feng; Jin Zhu; Xiao-hong Guan
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

3.  Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.

Authors:  Alexander B H Bakker; Wilfred E Marissen; R Arjen Kramer; Amy B Rice; William C Weldon; Michael Niezgoda; Cathleen A Hanlon; Sandra Thijsse; Harold H J Backus; John de Kruif; Bernhard Dietzschold; Charles E Rupprecht; Jaap Goudsmit
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Rabies-specific antibodies: measuring surrogates of protection against a fatal disease.

Authors:  Susan M Moore; Cathleen A Hanlon
Journal:  PLoS Negl Trop Dis       Date:  2010-03-09

5.  Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies.

Authors:  Samir K Lakhashe; Madhuri R Thakar; K E Bharucha; Ramesh S Paranjape
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

6.  Chicken galectin-1B inhibits Newcastle disease virus adsorption and replication through binding to hemagglutinin-neuraminidase (HN) glycoprotein.

Authors:  Junfeng Sun; Zongxi Han; Tianming Qi; Ran Zhao; Shengwang Liu
Journal:  J Biol Chem       Date:  2017-10-04       Impact factor: 5.157

7.  MARCH8 Targets Cytoplasmic Lysine Residues of Various Viral Envelope Glycoproteins.

Authors:  Yanzhao Zhang; Seiya Ozono; Takuya Tada; Minoru Tobiume; Masanori Kameoka; Satoshi Kishigami; Hideaki Fujita; Kenzo Tokunaga
Journal:  Microbiol Spectr       Date:  2022-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.